rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    AVTX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Here's Why Avalo Therapeutics (AVTX) is Poised for a Turnaround After Losing 40.4% in 4 Weeks

      Avalo Therapeutics (AVTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

      Nov 11Yahoo FinanceAVTX
      Stifel cuts Avalo Therapeutics stock price target on trial data
      Nov 6Investing.comAVTX
      Avalo Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Updates
      Nov 5Yahoo FinanceAVTX
      Avalo Therapeutics to Participate in Upcoming Investor Conferences

      WAYNE, Pa., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences: Guggenheim Healthcare Innovation ConferenceFireside ChatNovember 9, 2026 at 8:30am ET Stifel 2026 Healthcare ConferenceFireside ChatNovember 10, 2026 at 2:00pm ET Live webcasts a

      Nov 2Yahoo FinanceAVTX
      Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Avalo Therapeutics (AVTX)

      Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

      Oct 27The Globe and MailAVTX
      Exclusive BAC Article: Avalo Therapeutics; Positive Ph2 LOTUS Data Abdakibart HS, Phase 3 Start 1st Half 2027, IND Filing Next-Generation Long-Acting Anti-IL-1β Candidate Same Time, And Catalysts (NASDAQ:AVTX)
      Oct 26Seeking AlphaAVTX
      Oppenheimer cuts Avalo Therapeutics price target on trial concerns
      Oct 26Investing.comAVTX
      Avalo Therapeutics: Contrarian 'Buy' Ahead Of Abdakibart's Phase 3 (NASDAQ:AVTX)
      Oct 25Seeking AlphaAVTX
      Avalo Therapeutics Shares Fall After HC Wainwright Downgrade
      Oct 23Yahoo FinanceAVTX
      This Avalo Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
      Oct 23BenzingaAVTXGL
      Guggenheim downgrades Avalo Therapeutics stock rating on IL-1 data
      Oct 23Investing.comAVTX
      HC Wainwright Downgrades Avalo Therapeutics to Neutral From Buy
      Oct 23Yahoo FinanceAVTX
      Guggenheim Downgrades Avalo Therapeutics to Neutral From Buy
      Oct 23Yahoo FinanceAVTX
      Avalo Therapeutics Abdakibart Potential Intact After AbbVie Data, Wedbush Says
      Oct 22Yahoo FinanceAVTXABBV
      Wedbush Adjusts Avalo Therapeutics Price Target to $22 From $34, Maintains Outperform Rating
      Oct 22Yahoo FinanceAVTX
      H.C. Wainwright reiterates Avalo Therapeutics stock rating at buy
      Oct 16Investing.comAVTX
      Piper Sandler Keeps Their Buy Rating on Avalo Therapeutics (AVTX)

      Detailed price information for Avalo Therapeutics Inc (AVTX-Q) from The Globe and Mail including charting and trades.

      Oct 2The Globe and MailAVTX
      Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
      Sep 29Yahoo FinanceAVTX
      Avalo Therapeutics at Stifel forum: hs push gains traction
      Sep 24Investing.comAVTXSF
      Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress
      Sep 23Yahoo FinanceAVTX
      Avalo Therapeutics at H.C. Wainwright conference: phase 2 data lift outlook
      Sep 16Investing.comAVTX
      Cantor Fitzgerald reiterates Avalo Therapeutics stock rating
      Sep 16Investing.comAVTX
      Avalo Therapeutics at Cantor conference: building around il-1 beta
      Sep 10Investing.comAVTX
      Avalo Therapeutics: Phase 2 Validation Has Created An IL-1β Franchise (NASDAQ:AVTX)
      Sep 4Seeking AlphaAVTX
      Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

      WAYNE, Pa., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced the grant of inducement equity awards to six new employees. The Compensation Committee of the Board of Directors of Avalo approved the grants of nonstatutory stock options to purchase an aggregate of 78,000 shares of common stock (the “Options”) as

      Sep 4Yahoo FinanceAVTX
      Avalo Therapeutics to Participate in Upcoming Investor Conferences

      WAYNE, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences: Cantor Global Healthcare Conference 2026 Fireside ChatSeptember 10, 2026, at 8:00 am ET Morgan Stanley 24th Annual Global Healthcare Conference 1x1 meetings onlySeptember 16, 20

      Sep 3Yahoo FinanceAVTX
      Avalo Therapeutics CMO Mittie Doyle sells $20,000 in stock
      Sep 3Investing.comAVTX
      Avalo Therapeutics CFO Sullivan sells over $1.4m in stock
      Sep 2Investing.comAVTX
      Avalo Therapeutics chief medical officer Mittie Doyle sells $20,000 shares
      Aug 26Investing.comAVTX
      Avalo Therapeutics CFO sells over $1.45 million in stock
      Aug 25Investing.comAVTX

      This is the newest page. Registered accounts read further back.